Advance in Diagnosis and Management of Endometrial Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 120
Special Issue Editor
Interests: cancer biology; gynecologic oncology; tumor biomarkers; cancer diagnostics; breast cancer; ovarian cancer; endometrial cancer; vulvar cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Endometrial cancer is the most common gynecological malignancy and the fourth most common cancer in women in developed countries. The incidence and mortality of endometrial cancer are increasing due to the aging population, obesity epidemic, and lack of effective screening methods. Endometrial cancer is a heterogeneous disease with different histological subtypes, molecular alterations, and clinical outcomes. The current diagnosis and management of endometrial cancer are mainly based on histopathological features, surgical staging, and risk stratification. However, these parameters have limitations in predicting the prognosis and response to treatment of individual patients. Therefore, there is an urgent need for novel biomarkers and therapeutic strategies that can improve the accuracy of diagnosis, prognosis, and personalized treatment of endometrial cancer. This special issue aims to provide an update on the recent advances in the understanding of the pathogenesis, molecular classification, and targeted therapy of endometrial cancer. It will cover topics such as the role of genetic and epigenetic factors, hormonal and metabolic pathways, immune and inflammatory responses, and microenvironmental factors in endometrial carcinogenesis and progression; the application of molecular and genomic tools in the diagnosis, prognosis, and prediction of treatment response of endometrial cancer; the development and evaluation of novel targeted agents and immunotherapies for endometrial cancer; and the challenges and opportunities in the clinical management of endometrial cancer. We invite researchers and clinicians to submit original research articles, reviews, and commentaries that will contribute to the advancement of the field of endometrial cancer.
Dr. Fulvio Borella
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biology
- gynecologic oncology
- tumor biomarkers
- cancer diagnostics
- breast cancer
- ovarian cancer
- endometrial cancer
- vulvar cancer
